A Commonwealth Fund study finds Black and Hispanic Ohioans face much higher avoidable‑death rates, uninsured rates and cost‑related care gaps than other groups.

Amazon pairs GLP‑1 drugs with One Medical primary care, same‑day delivery and on‑demand renewals — a push that speeds access but may shift business from local pharmacies.

Tom Golisano pledged $50 million to Akron Children’s — the largest gift in the hospital’s history — and Akron27s main campus will be rebranded as part of the Golisano Children27s Alliance.

CMS inspection records and advocates say Ohio nursing homes have discharged medically fragile residents to homeless shelters, often without prescriptions or follow‑up care.

A North Ridgeville father is receiving liver-directed chemotherapy through an implanted pump at UH Seidman, a targeted approach meant to reduce side effects and buy time.

A KFF poll finds one‑third of U.S. adults used AI chatbots for health information, often because care is costly or hard to access.

The Mandel Foundation pledged $50 million to Cleveland Clinic for its planned Level I trauma center and a related initiative, a move that could reshape regional trauma care. Local hospitals have already pushed back.

Girard and Struthers have met with QUICKmed about clinics that would waive visit fees for residents, with officials eyeing grant funding and a pilot rollout.

Family members say an 80-year-old resident was found bruised and sometimes left in her own waste. Public inspection records show repeated deficiencies and federal fines.

Cardinal Health has recalled hundreds of lots of Webcol alcohol prep pads after a sterilization audit found bacterial contamination. Hospitals and clinics are being urged to quarantine and return affected stock immediately.

An analysis of PROMISE trial CT scans found women’s heart risk rises at lower plaque burdens than men, even though women had less plaque overall. Researchers say sex-specific thresholds may be needed.

KFF and CDC figures show opioid deaths fell roughly 32% in 2024, and Ohio’s decline outpaced many states as officials credit naloxone, treatment and new early‑warning tools.

A Cleveland‑led trial validated the PAM50 genomic test, identifying men with luminal B recurrent prostate tumors who benefit from adding apalutamide to salvage radiation.